Glucagon like Peptide 1 News and Research

RSS

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof

This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, inflammatory, mitochondrial, and proteostasis pathways. Evidence from mechanistic, preclinical, and early clinical studies suggests potential neuroprotective effects, but definitive disease-modifying benefit remains unproven.

17 Feb 2026

Do cocoa flavanols influence heart and fatty liver risk factors?

A recent Nutrients review examined whether cocoa-rich dark chocolate influences cardiovascular and metabolic dysfunction-associated steatotic liver disease risk factors through antioxidant, anti-inflammatory, and endothelial effects. Evidence suggests modest improvements in biomarkers, but most data come from short-term studies, so definitive clinical benefits remain unproven.

16 Feb 2026

Ozempic users continue treatment when weight loss works despite side effects

A study on Ozempic for weight loss reveals user satisfaction is driven by efficacy, despite common gastrointestinal side effects impacting treatment adherence.

13 Feb 2026

Weight loss drug tirzepatide may lower the risk of diabetic retinopathy

The popular diabetes and weight loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators.

11 Feb 2026

Semaglutide lowers cardiovascular events even without major weight loss, researchers report

Semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease regardless of baseline adiposity. Cardiovascular benefit was largely independent of overall weight loss, with waist circumference reduction explaining only part of the effect.

11 Feb 2026

Tirzepatide shows dual benefits in sleep apnea trial improving metabolism and reducing inflammation

Tirzepatide significantly improved cardiometabolic risk markers in adults with obesity and moderate to severe obstructive sleep apnea in the SURMOUNT-OSA phase 3 trials. Mediation analyses suggest both weight loss and reduced sleep-disordered breathing contributed to improvements in inflammation, insulin resistance, lipids, and blood pressure.

9 Feb 2026

Unprocessed beef does not worsen metabolic health in prediabetes

Short-term unprocessed beef intake shows no adverse effects on glucose regulation or metabolic health compared to poultry in individuals with prediabetes.

2 Feb 2026

New trial tests strategies to protect heart health during prostate cancer therapy

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened a phase 2 clinical trial comparing three different strategies for protecting heart health in prostate cancer patients who receive androgen deprivation therapy (ADT), a potentially lifesaving hormone therapy.

26 Jan 2026

Why exercise is essential for restoring fitness after GLP-1-based weight loss

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in adults with obesity. In contrast, liraglutide alone sustains weight loss but does not significantly improve measured physical fitness outcomes.

26 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

GLP-1 weight-loss drugs show early promise for treating addiction

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions in drug- and alcohol-seeking behaviors in animal models, while human evidence remains limited, heterogeneous, and preliminary.

21 Jan 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026

High-dose flu shots lower hospitalization risk in older adults

High-dose influenza vaccines may lower serious hospitalization rates in older adults, particularly those with diabetes, according to a recent Danish trial.

20 Jan 2026

Bariatric surgery reshapes body fat and muscle more than GLP-1 drugs

Bariatric surgery and GLP-1 treatments reshape body composition differently, emphasizing the importance of sex and treatment choice in muscle preservation.

14 Jan 2026

Most patients regain lost weight within two years of stopping obesity drugs

Weight management medications show limited long-term effects, with rapid weight regain post-treatment, emphasizing the need for sustainable obesity strategies.

13 Jan 2026

Why adherence determines weight loss success with semaglutide

Researchers examine how the effectiveness of weight-loss medications may depend on the patient adherence.

12 Jan 2026

Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK

In early 2025, around 4.9 million British adults - almost one in ten - are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The findings, which are based on a nationally representative household survey of 5,260 British adults, are published in BMC Medicine.

8 Jan 2026

Weight loss drugs may cause nutritional deficiencies without proper guidance

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.

7 Jan 2026

Millions in Great Britain using or seeking weight loss drugs

An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according to a new study by UCL (University College London) researchers.

7 Jan 2026